Pioglitazone and metformin in fixed dose combination

Takeda UK Ltd has introduced a fixed dose combination of pioglitazone (15mg) and metformin (850mg) under the brand name of Competact.

Competact is indicated for the treatment of type 2 diabetes, particularly in overweight patients, who are unable to achieve sufficient glycaemic control at maximally tolerated doses of metformin alone.

The usual dose is one tablet twice daily. Dose titration with pioglitazone added to the optimal dose of metformin should be considered before switching the patient to the fixed dose combination, but when clinically appropriate a direct switch from metformin monotherapy can be made. Pharmacokinetic studies in healthy volunteers have shown the fixed dose combination to be bioequivalent to the two drugs given as separate tablets.

Further information: Takeda UK Ltd, Takeda House, The Mercury Park, Wycombe Lane, High Wycombe, Buckinghamshire HP10 0HH. Tel: (01628) 537900.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases